BIOMAT Database Logo BIOMAT Database Logo

[Effect of oxandrolone on the serum lipids in type IV and IIb hyperlipidemia]. 1973

E Zorrilla, and C Magos, and P A Serrano

UI MeSH Term Description Entries
D006949 Hyperlipidemias Conditions with excess LIPIDS in the blood. Hyperlipemia,Hyperlipidemia,Lipemia,Lipidemia,Hyperlipemias,Lipemias,Lipidemias
D008074 Lipoproteins Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes. Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010074 Oxandrolone A synthetic hormone with anabolic and androgenic properties. Anavar,Oxandrin,SC-11585,SC 11585,SC11585
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D004040 Dietary Carbohydrates Carbohydrates present in food comprising digestible sugars and starches and indigestible cellulose and other dietary fibers. The former are the major source of energy. The sugars are in beet and cane sugar, fruits, honey, sweet corn, corn syrup, milk and milk products, etc.; the starches are in cereal grains, legumes (FABACEAE), tubers, etc. (From Claudio & Lagua, Nutrition and Diet Therapy Dictionary, 3d ed, p32, p277) Carbohydrates, Dietary,Carbohydrate, Dietary,Dietary Carbohydrate
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

E Zorrilla, and C Magos, and P A Serrano
[The effect of xanthinol nicotinate on the serum lipids and lipoproteins of patients with primary hyperlipoproteinemia Type IIb and IV].
January 1976, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
E Zorrilla, and C Magos, and P A Serrano
[Evaluation of the efficiency of gemfibrozil in treating hyperlipidemia type IIb and IV].
January 1994, Polskie Archiwum Medycyny Wewnetrznej,
E Zorrilla, and C Magos, and P A Serrano
[Serum cholesterol in endogenous hyperlipidemia (type IV)].
November 1972, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
E Zorrilla, and C Magos, and P A Serrano
Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
January 1980, Artery,
E Zorrilla, and C Magos, and P A Serrano
[Modification of serum lipids, lipoproteins and apoproteins AI and B in patients with hyperlipidemia Type IIa and IIb using polyenylphosphatidylcholine].
July 1985, Schweizerische medizinische Wochenschrift,
E Zorrilla, and C Magos, and P A Serrano
[Effect of CRP preparation on serum lipids in patients with hyperlipidemia].
May 1993, Wiadomosci lekarskie (Warsaw, Poland : 1960),
E Zorrilla, and C Magos, and P A Serrano
Effect of probucol on plasma lipids and lipoproteins in type IIb hyperlipoproteinemia.
November 1980, Atherosclerosis,
E Zorrilla, and C Magos, and P A Serrano
Effects of oxandrolone on plasma lipoproteins in patients with type IIa, IIb and IV hyperlipoproteinemia: occurrence of hypo-high density lipoproteinemia.
February 1979, Artery,
E Zorrilla, and C Magos, and P A Serrano
[Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV].
April 1982, Die Medizinische Welt,
E Zorrilla, and C Magos, and P A Serrano
[Turnover of triglycerides in "very low density" lipoproteins in hyperlipidemia type IIb and IV. Preliminary communication].
October 1976, Die Medizinische Welt,
Copied contents to your clipboard!